The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis

Karadağ, Şerife Gül; Aktay Ayaz, Nuray; Tanatar, Ayşe; Çakan, Mustafa

doi:10.14744/nci.2019.57873

The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis

Mustafa ÇAKAN, (Sağlık Bilimleri Üniversitesi, Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi, Çocuk Romatoloji Kliniği, İstanbul, Türkiye)

Nuray AYAZ, (Sağlık Bilimleri Üniversitesi, Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi, Çocuk Romatoloji Kliniği, İstanbul, Türkiye)

Şerife KARADAĞ, (Sağlık Bilimleri Üniversitesi, Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi, Çocuk Romatoloji Kliniği, İstanbul, Türkiye)

Ayşe TANATAR (Sağlık Bilimleri Üniversitesi, Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi, Çocuk Romatoloji Kliniği, İstanbul, Türkiye)

İstanbul Kuzey Klinikleri

6 0

Yıl: 2020 Cilt: 7 Sayı: 2 Sayfa Aralığı: 118 - 123 Metin Dili: İngilizce DOI: 10.14744/nci.2019.57873 İndeks Tarihi: 17-09-2020

The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis

Öz:

OBJECTIVE: Juvenile idiopathic arthritis (JIA) is the most common cause of chronic arthritis in children. Biologics havechanged the faith of children with rheumatic diseases. The main objective of this study was to demonstrate the rate of usage,efficacy and safety of biologics in JIA subtypes.METHODS: This retrospective observational cohort study was conducted between May 2010 and September 2017. All children with the diagnosis of JIA and children under a biological agent treatment were recorded into the local registry system.Age, gender, JIA subtype, medications used, the clinical status of the patient, tuberculosis screening results, and side effectsobserved under biologics were retrieved from the registry.RESULTS: There were 405 patients with the diagnosis of JIA in the cohort. Biologics were used in 123 (30.3%) JIA patients. Subtype frequencies of JIA patients were as follows: persistent oligoarticular JIA (33.6%), enthesitis-related arthritis(29.2%), systemic JIA (13%), rheumatoid factor (RF)-negative polyarticular JIA (13%), extended oligoarticular JIA (4.2%),RF-positive polyarticular JIA (3.4%), psoriatic arthritis (1.8%) and unclassified arthritis (1.8%). The rate of biologic use washigh in extended oligoarticular JIA (64.7% of the cases), RF-positive polyarticular JIA (57.1%), psoriatic arthritis (57.1%), RFnegative polyarticular JIA (41.5%), and in systemic JIA (39.6%). Enthesitis-related arthritis (27.1%), persistent oligoarticularJIA (17.6%) and unclassified arthritis (16.6%) patients were the cases that needed a biologic agent in the last order. At thelast control, 78.9% of the cases were in remission, while 21.1% of them were active despite biologic treatment. Isoniazidprophylaxis was used in 30.8% of the patients. None of the patients developed active tuberculosis infection under prophylaxis. Adverse events were observed in 18.6% of patients under biologics as recurrent uncomplicated upper respiratory tractinfections being the most common.CONCLUSION: Biologics are safe and effective treatment options in children with JIA. Most of the JIA patients with polyarticular involvement require biologics earlier in the disease course. The risk of tuberculosis infection seems not to be increasedafter appropriate screening and prophylaxis.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2.
2. Batu ED, Sönmez HE, Gülhan B, Arıcı ZS, Topaloğlu R, Bilginer Y. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis. Turk J Pediatr 2017;59:6–12.
3. Gümüş D, Başaran Ö, Çakar N, Uncu N, Çelikel Acar B. Evaluation of childhood health assessment questionnaire in juvenile idiopathic arthritis: A single center experience from Turkey. Arch Rheumatol 2015;30:57–62.
4. Consolaro A, Giancane G, Alongi A, van Dijkhuizen EHP, Aggarwal A, Al-Mayouf SM, et al. Phenotypic variability and disparities in treat- ment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health 2019;3:255–63.
5. Demirkaya E, Ozen S, Bilginer Y, Ayaz NA, Makay BB, Unsal E, et al. The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clin Exp Rheumatol 2011;29:111–6.
6. Çakan M, Aktay-Ayaz N, Keskindemirci G, Ekinci DY, Karadağ ŞG. Subtype frequencies, demographic features and remission rates in juvenile idiopathic arthritis – 265 cases from a Turkish center. Turk J Pediatr 2017;59:548–54.
7. Gökçe İ, Demirkaya E. New treatment strategies in the treatment of juvenile idiopathic arthritis. Turk J Rheumatol 2011;26:71–85.
8. Baris HE, Anderson E, Sozeri B, Dedeoglu F. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis. Clin Rheumatol 2018;37:3263–73.
9. Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis 2018;77:819–28.
10. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Paediatric Rheumatology International Trials Organisation. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011;63:929– 36.
11. Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Е, et al; Paediatric Rheumatology International Trials Organisation (PRINTO), BiKeR and the board of the Swedish Registry. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther 2018;20:285.
12. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763–9.
13. Vanoni F, Minoia F, Malattia C. Biologics in juvenile idiopathic arthritis: a narrative review. Eur J Pediatr 2017;176:1147–53.
14. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810–20.
15. Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, WellerHeinemann F, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther 2016;18:272.
16. Nalbanti P, Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Farmaki E, Bamidis P, et al. Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment. Rheumatol Int 2018;38:1241–50.
17. Camlar SA, Makay B, Appak O, Appak YC, Esen N, Günay T, et al. Performance of tuberculin skin test and interferon gamma assay for the diagnosis of latent tuberculosis infection in juvenile idiopathic arthritis. Clin Rheumatol 2011;30:1189–93.
18. Lee H, Park HY, Jeon K, Jeong BH, Hwang JW, Lee J, et al. QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment. PLoS One 2015;10:e0119260.
19. Jung YJ, Woo HI, Jeon K, Koh WJ, Jang DK, Cha HS, et al. The Significance of Sensitive Interferon Gamma Release Assays for Diagnosis of Latent Tuberculosis Infection in Patients Receiving Tumor Necrosis Factor-α Antagonist Therapy. PLoS One 2015;10:e0141033.
20. Kiray E, Kasapcopur O, Bas V, Kamburoglu-Goksel A, Midilli K, Arisoy N, et al. Purified protein derivative response in juvenile idiopathic arthritis. J Rheumatol 2009;36:2029–32.
21. Barut K, Şahin S, Adrovic A, Köşker M, Kılıç Ö, Camcıoğlu Y, et al. Tuberculin skin test response in patients with juvenile idiopathic arthritis on anti-TNF therapy. Turk J Med Sci 2018;48:1109–14.
22. Ayaz NA, Demirkaya E, Bilginer Y, Ozçelik U, Cobanoğlu N, Kiper N, et al. Preventing tuberculosis in children receiving anti-TNF treatment. Clin Rheumatol 2010;29:389–92.
23. Brunelli JB, Bonfiglioli KR, Silva CA, Kozu KT, Goldenstein-Schainberg C, Bonfa E, et al. Latent tuberculosis infection screening in juvenile idiopathic arthritis patients preceding anti-TNF therapy in a tuberculosis high-risk country. Rev Bras Reumatol Engl Ed 2017;57:392–6.
24. Aeschlimann FA, Chong SL, Lyons TW, Beinvogl BC, Góez-Mogollón LM, Tan S, et al. Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and MetaAnalyses. J Pediatr 2019;204:162–71.e3.
25. Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 2010;62:3776–82.
26. Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, et al; Safety Assessment of Biological Therapeutics Collaboration. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64:1263–71.
27. Beukelman T, Xie F, Chen L, Horton DB, Lewis JD, Mamtani R, et al. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Ann Rheum Dis 2018;77:1012–6.

APA	Çakan M, Aktay Ayaz N, Karadağ Ş, Tanatar A (2020). The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. , 118 - 123. 10.14744/nci.2019.57873
Chicago	Çakan Mustafa,Aktay Ayaz Nuray,Karadağ Şerife Gül,Tanatar Ayşe The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. (2020): 118 - 123. 10.14744/nci.2019.57873
MLA	Çakan Mustafa,Aktay Ayaz Nuray,Karadağ Şerife Gül,Tanatar Ayşe The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. , 2020, ss.118 - 123. 10.14744/nci.2019.57873
AMA	Çakan M,Aktay Ayaz N,Karadağ Ş,Tanatar A The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. . 2020; 118 - 123. 10.14744/nci.2019.57873
Vancouver	Çakan M,Aktay Ayaz N,Karadağ Ş,Tanatar A The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. . 2020; 118 - 123. 10.14744/nci.2019.57873
IEEE	Çakan M,Aktay Ayaz N,Karadağ Ş,Tanatar A "The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis." , ss.118 - 123, 2020. 10.14744/nci.2019.57873
ISNAD	Çakan, Mustafa vd. "The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis". (2020), 118-123. https://doi.org/10.14744/nci.2019.57873

APA	Çakan M, Aktay Ayaz N, Karadağ Ş, Tanatar A (2020). The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. İstanbul Kuzey Klinikleri, 7(2), 118 - 123. 10.14744/nci.2019.57873
Chicago	Çakan Mustafa,Aktay Ayaz Nuray,Karadağ Şerife Gül,Tanatar Ayşe The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. İstanbul Kuzey Klinikleri 7, no.2 (2020): 118 - 123. 10.14744/nci.2019.57873
MLA	Çakan Mustafa,Aktay Ayaz Nuray,Karadağ Şerife Gül,Tanatar Ayşe The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. İstanbul Kuzey Klinikleri, vol.7, no.2, 2020, ss.118 - 123. 10.14744/nci.2019.57873
AMA	Çakan M,Aktay Ayaz N,Karadağ Ş,Tanatar A The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. İstanbul Kuzey Klinikleri. 2020; 7(2): 118 - 123. 10.14744/nci.2019.57873
Vancouver	Çakan M,Aktay Ayaz N,Karadağ Ş,Tanatar A The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis. İstanbul Kuzey Klinikleri. 2020; 7(2): 118 - 123. 10.14744/nci.2019.57873
IEEE	Çakan M,Aktay Ayaz N,Karadağ Ş,Tanatar A "The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis." İstanbul Kuzey Klinikleri, 7, ss.118 - 123, 2020. 10.14744/nci.2019.57873
ISNAD	Çakan, Mustafa vd. "The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis". İstanbul Kuzey Klinikleri 7/2 (2020), 118-123. https://doi.org/10.14744/nci.2019.57873